{"groups":[{"description":"Participants received intravenous bortezomib on a 3-week dosing cycle: 1.3 mg/m2 on days 1, 4, 8 and 11 followed by 10 day rest period for up to 8 cycles or for 2 cycles beyond complete response. Participants with progressive disease or unacceptable toxicity discontinued treatment.","id":"FG000","title":"Bortezomib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lack of Response"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Non-Protocol Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal of Consent before Trt"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Progressive Disease before Trt"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"66"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"64"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"30"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"66 participants were enrolled between December 2003 and September 2005."}